Providers utilize business intelligence to monitor referral patterns and collaborate with clinicians who order their services. Such analytics tools have also been deployed in the specialty to improve productivity, track patient satisfaction and bolster quality.
With its $350M in new funding, EliseAI said it plans to build out its technology and sales force. It currently works with specialty provider groups to automate practice operations such as scheduling and insurance verification.
Of surveyed and interviewed U.S. physicians who showed significant six-month improvement in follow-up vs. baseline wellness checks, 47% attributed the gain to active personal changes. Not far behind were those who credited active work-related changes—40% of the field.
The new entity, Precure, will be owned by both groups. Its work in detecting early disease for timely intervention stems from a research project launched this summer. The Mayo Clinic said Precure will make the results of that initiative actionable.
Parmjit “Paul” Parmar, 55, from New Jersey has also been ordered to pay $125 million in restitution. The scheme to defraud investors was uncovered in 2017.
The insurance arm of UnitedHealth Group said the shift is part of its ongoing effort to eliminate the barriers between care delivery and medical coverage. The full list of services exempt from prior authorizations includes diagnostic tests and many outpatient surgeries.
WakeMed, a three-hospital system in the North Carolina capital region of Raleigh, would become part of Advocate Health, Atrium’s parent company, if the deal goes through. Advocate is one of the largest not-for-profit health systems in the U.S.
The New Jersey-based drug developer joins AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer in offering products directly to patients at a discounted rate. Johnson & Johnson is currently listing four medications on the platform.
The agency said it is seeking to exclude semaglutide, tirzepatide and liraglutide from the 503B program based on a lack of clinical evidence. Unless there’s a shortage, the pharmaceuticals would be barred from being compounded by third-parties for the purpose of treating diabetes or obesity. The FDA is seeking public comment on the proposal.